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vs MM (41%), HL (40%) and AL/LCD (23%); p ¼ 0.004. The
median number of CD34 cells collected was 7.4 million/kg
(IQR 5.2- 9.9). Median CD34 collection was highest for MM
and AL/LCD, reﬂecting the practice to collect for more than
one transplant. Overall 9 (<1%) and 22 (2%) patients collected
< 2 million and < 2.5 million CD34 cells/kg, respectively.
More patients with NHL (4%) collected < 2.5 million/kg
compared with MM (1%), AL/LCD (2%) and HL (0%), p¼0.02.
The median number of days of apheresis was 2 (IQR 1-3) and
was higher in the NHL group (p¼0.002). The median CD34
collected per day was 3.6 million/ kg (IQR 2-5.8); higher in
MM and AL/LCD vs NHL and HL (p < 0.001). The median
CD34 collection was very similar for those patients getting
plerixafor versus those not requiring plerixafor (p¼0.26). The
median time to ANC and platelet engraftment were 14 days
(IQR 13-16) and 13 days (IQR 12-15), respectively. While
there was no difference in ANC engraftment, platelet
engraftment was longer among patients requiring plerixafor.
Conclusion: This data conﬁrms the effectiveness of this risk
adapted algorithm in over 1000 patients over 4 years. The
mobilization failure rate remains low. Approximately 45% of
patients did not require plerixafor, supporting the use of this
risk adapted algorithm to select appropriate patients who
require plerixafor.CLINICAL CELLULAR THERAPY32
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Cancer immunotherapy with NK cells is promising, but a
key challenge is the development of a method that can
consistently expand NK cells from a small fraction (w5%)
of unselected PBMCs to a therapeutically effective dose
while using “off the shelf” reagents, not requiring long-
term complex co-cultures, and with low doses of IL-2.
Methods that use feeder cells do expand NK cells, but
require complex procedures with prolonged ex vivo co-
culture with the feeder cells, are costly, are logistically
difﬁcult, and require subsequent administration of high
dose IL-2 for persistence after injection. We developed a
particle-based method to speciﬁcally expand cytotoxic NK
cells from unselected PBMCs. These particles, prepared
from plasma membrane (PM) of engineered K562 cells
that express cytokines such as IL-21 or IL-15 and 41BBL,
stimulate in vitro and in vivo expansion of NK cells. In vitro,
these PM-particles containing membrane bound IL-21
(PM21-particles) cause highly speciﬁc expansion of cyto-
toxic NK cells from unselected PBMCs by achieving >90%
NK cells in 14 days and 104 fold expansion of NK in 21
days. NK cell expansion is consistent with different prep-
arations of PM-particles or leukocyte sources, and the PM-
particles retain expansion efﬁcacy with -80C storage.
The PM21-particles also stimulate in vivo NK cell expan-
sion in NSG mice under ultralow IL-2 (1,000 U per injec-
tion, 3 x weekly). The efﬁcacy of ex vivo pre-activation
with PM21, prior to injection, was tested by injecting
PBMCs (2 x 106 PBMCs per mice, i.p., 6 mice per group),which were either activated in culture for two days with
200 mg/mL PM21 (PM21-PBMCs) or not pre-activated
(PBMCs), and then the abundance of hCD56+CD3- NK cells
and other hCD45+ lymphocytes were monitored in pe-
ripheral blood of mice. Clear efﬁcacy for pre-activation
was observed where the mice in the group given PM21-
PBMCs had 66 fold higher human NK (hNK) cells as
compared to the group injected with PBMCs. The efﬁcacy
of administering PM21-particles in vivo was examined also
where 2 x 106 PM21-PBMCs, were injected i.p. into mice (4
mice per group) that then received 0, 400, 800 or 1600 mg
of PM21 (i.p., 2 x weekly). The mice injected with 800 mg of
PM21 had the highest amount of hNK cells averaging
890,000 hNK/mL of mouse blood on day 16 and reaching
95  2% of total hCD45+ cells by day 12. By comparing the
averages between day 5 and 16 in this experimental group,
hNK cell increased a minimum of 390 fold in the mouse
blood. Furthermore, examination of organs from mice
sacriﬁced on day 16 after PM21-PBMC injection shows
signiﬁcant numbers of hNK cells in bone marrow, spleen,
lung, liver and brain. The extent of NK cells observed in
the peripheral blood (>50,000 NK cells/mL blood, 14 days
post injection) and biodistribution to sites of disease
would be relevant for clinical cancer treatment, and thus
shows that PM-particle technology could be suitable for
NK cell immunotherapy.33
CMVpp65-Speciﬁc T Cells Generated from Naïve T Cell
Populations Recognize Atypical but Not Canonical
Epitopes and May Be Protective In Vivo
Patrick J. Hanley 1, Jan Melenhorst 2, Sarah Nikiforow 3,
Phillip Scheinberg 4, Russell Cruz 5, Robert A. Krance 6,
Kathryn Leung 7, Caridad Martinez 7, Helen E. Heslop 8,
Cliona M. Rooney 8, A. John Barrett 9, Elizabeth J. Shpall 10,
Catherine M. Bollard 11. 1 CETI, Blood and Marrow
Transplantation, Children’s National Medical Center,
Washington, DC; 2Hematology, National Institutes of Health,
National Heart, Lung, and Blood Institute, Bethesda, MD;
3Hematologic Malignancies, Dana-Farber Cancer Institute,
Harvard Medical School, Boston, MA; 4 Antonio Ermirio de
Moraes Oncology Center, Hospital Beneﬁcência Portuguesa de
São Paulo, Sao Paulo, Brazil; 5 Sheikh Zayad Institute, Children’s
National Medical Center, Washington, DC; 6 Center for Cell and
Gene Therapy, Baylor College of Medicine, Houston Methodist
Hospital and Texas Children’s Hospital, Houston, TX; 7 Center
for Cell and Gene Therapy, Baylor College of Medicine, Texas
Children’s Hospital, Houston, TX; 8 Center for Cell and Gene
Therapy, Baylor College of Medicine, Texas Children’s Hospital,
Houston Methodist Hospital, Houston, TX; 9Hematology
Branch, National Heart, Lung, and Blood Institute, NIH,
Bethesda, MD; 10 Stem Cell Transplantation and Cellular
Therapy, The University of Texas MD Anderson Cancer Center,
Houston, TX; 11 Center for Cancer and Immunology Research,
Children’s National Medical Center, Washington, DC
Adoptive transfer of CMVpp65-speciﬁc T-cells (cCTL) from
CMV-seropositive (CMVpos) donors effectively restores
antiviral-immunity after stem cell transplantation. However,
the naïve T-cells in cord blood(CB) and adult CMV-serone-
gative(CMVneg) donors require different culture systems to
generate cCTL. With a novel GMP-applicable protocol we
have reliably generated cCTL from CB and CMVnegs and
found that of >20 T-cell lines, all recognized atypical epi-
topes of pp65. HLA-A2+ cCTL derived from naive T-cells
recognized novel pp65 epitopes (e.g. LQT) but not the
typical epitope NLV. Analysis of the avidity of naïve donor
